Submitted for Publication: August 22, 2014; final revision received February 18, 2015; accepted February 19, 2015.
Published Online: June 24, 2015. doi:10.1001/jamapsychiatry.2015.0270.
Study concept and design: Subotnik, Casaus, Marder, Nuechterlein.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Subotnik, Hellemann, Nuechterlein.
Critical revision of the manuscript for important intellectual content: Subotnik, Casaus, Ventura, Luo, Gretchen-Doorly, Marder, Nuechterlein.
Statistical analysis: Subotnik, Hellemann, Nuechterlein.
Obtained funding: Subotnik, Ventura, Nuechterlein.
Administrative, technical, or material support: Subotnik, Casaus, Ventura, Luo, Gretchen-Doorly, Nuechterlein.
Study supervision: Subotnik, Casaus, Ventura, Luo, Marder, Nuechterlein.
Conflict of Interest Disclosures: Dr Subotnik reports serving as a consultant to Janssen Scientific Affairs, LLC; being on the speaker’s bureau for Otsuka America Pharmaceutical, Inc; and receiving research support from Janssen Scientific Affairs, LLC, and Genentech Inc, through grants to Drs Nuechterlein and Ventura. Dr Ventura reports serving as a consultant to Posit Science Corporation and Boehringer-Ingelheim GmbH and receiving research support from Janssen Scientific Affairs, LLC, Posit Science Corporation, and Genentech Inc. Dr Marder reports receiving consulting fees from AbbVie, Pfizer, Lundbeck, Boeringer Ingelheim GmbH, Shire Plc, Roche, Genentech Inc, Takeda Pharmaceutical Company Ltd, Jazz Pharmaceuticals, Otsuka America Pharmaceutical, Inc, Targacept, and FORUM Pharmaceuticals and grant support from Amgen, Synchroneuron, and Sunovion. Dr Nuechterlein reports serving as a consultant to Genentech Inc, Janssen Scientific Affairs, LLC, Otsuka America Pharmaceutical, Inc, and Janssen-Cilag and receiving support from Janssen Scientific Affairs, LLC, Posit Science Corporation, and Genentech Inc. No other disclosures were reported.
Funding/Support: This research was supported by grants MH037705 (clinicalTrials.gov Identifier: NCT00333177) and MH066286 (clinicalTrials.gov Identifier: NCT00330551) from the National Institute of Mental Health (Dr Nuechterlein) and supplementary funding and medication was provided by Janssen Scientific Affairs, LLC.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, or Janssen Scientific Affairs, LLC.
Additional Contributions: We thank the patients for their participation in this longitudinal study. Walter Dunn, MD, PhD, Department of Psychiatry and Behavioral Sciences, UCLA, commented on the analysis of plasma assays. Kimberly Baldwin, MFT, Rosemary Collier, MA, Nicole R. DeTore, MA, Yurika Sturdevant, PsyD, and Luana Turner, PsyD, UCLA Aftercare Research Program, served as case managers. Elisha Agee, Elizabeth Arreola, BS, Manjot Bains, Miriam Barillas, BS, Ashton Christian, Kassandra Coronel, Liset Cristino Crespin, BS, Jing Gong, Angie Sung Hyun Lim, Sabiha Kaiser, Steven Kwong, Lilian Medina, BS, Gabriella Pasqual, Leila Sims, Gabriel Swerdlow, John Tran, Andres Victoria, BS, Yejin Yoo, and Liang Zhu rated medication adherence. Mss Arreola, Barillas, Cristino Crespin, and Medina and Mr Victoria were paid research assistants. No others were financially compensated.